title: Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke.
abstract: OBJECTIVE
  Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage.
  
  
  METHODS
  The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group.
  
  
  RESULTS
  Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019).
  
  
  CONCLUSIONS
  Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.
authors: Department of Neurology, Medical College of Georgia, 1122 15th Street, Augusta, GA 30912, USA. jswitzer@georgiahealth.edu
authors: Jeffrey A
authors: JA
authors: Switzer
authors: David C
authors: DC
authors: Hess
authors: Adviye
authors: A
authors: Ergul
authors: Jennifer L
authors: JL
authors: Waller
authors: Livia S
authors: LS
authors: Machado
authors: Vera
authors: V
authors: Portik-Dobos
authors: L Creed
authors: LC
authors: Pettigrew
authors: Wayne M
authors: WM
authors: Clark
authors: Susan C
authors: SC
authors: Fagan
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002545:Brain Ischemia / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D061965:Matrix Metalloproteinase Inhibitors; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage*; D020521:Stroke / Q000097:blood* / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents; D005343:Fibrinolytic Agents; D061965:Matrix Metalloproteinase Inhibitors; D010959:Tissue Plasminogen Activator; D020780:Matrix Metalloproteinase 9; D008911:Minocycline